Andere talen Galmed Pharmaceuticals Ltd.

Aandelen

GLMD

IL0011313900

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 30-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,352 ^USD	-7,12%		-2,60%	-22,64%

04/04	Galmed Pharmaceuticals Ltd. Rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
15/03	Galmed Pharmaceuticals Ltd. Kondigt de toekenning van een nieuw patent aan voor de combinatie van Aramchol met Resmetirom (MGL-3196, REZDIFFRA) voor de behandeling van Nash en leverfibrose	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04/04
Galmed Pharmaceuticals Ltd. Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of Nash and Liver Fibrosis	15/03
Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis	15/03
Galmed Pharmaceuticals : Consolidated Financial Statements - Form 6-K	22/11
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	22/11
Sector Update: Health Care Stocks Higher Late Tuesday Afternoon	21/11
Sector Update: Health Care	21/11
Top Midday Decliners	21/11
Galmed Pharmaceuticals Expects Minimum Six Months Delay in Primary Sclerosing Cholangitis Study	20/11
Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study	20/11
Galmed Pharmaceuticals Ltd. Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis	26-09-23
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification	25-09-23
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification	22-09-23
Galmed Pharmaceuticals: Q2 Earnings Snapshot	10-08-23
Galmed Pharmaceuticals : 16 Tiomkin St. Tel Aviv 6578317, Israel - Form 6-K	09-08-23
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09-08-23
Galmed Pharmaceuticals : Securities Purchase Agreement - Form 6-K	18-07-23
Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering	17-07-23
Top Midday Decliners	14-07-23
Galmed Pharmaceuticals Prices $7 Million Securities Offering; Shares Slump	14-07-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Galmed Pharmaceuticals Ltd.

Aandelen

GLMD

IL0011313900

Andere talen

Filters